ArticleMetabolic brain disease2026
AMPK activation by Aldometanib from Bigujing improves metabolic and cognitive dysfunction in aging mice.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging-related cognitive decline is closely associated with disrupted energy metabolism and impaired autophagic clearance in the brain. Aldometanib, an active ingredient from the traditional formulation Bigujing, exerts systemic metabolic benefits, but its effects on brain aging and the underlying mechanisms remain unclear. This study aims to evaluate the efficacy of Aldometanib in mitigating cognitive decline in D-galactose-induced aging mice, and to elucidate its potential mechanisms involving AMPK-mediated energy metabolism and autophagy regulation. Male C57BL/6 J mice were treated with D-gal for 42 days, with or without 100 μg/mL Aldometanib in drinking water. Cognitive function was evaluated using the novel object recognition test, Y-maze test, and the Morris water maze test. Brain tissues were analyzed for neuronal morphology, the total antioxidant capacity (T-AOC) and the expressions of senescence, AMPK/ACC pathway and autophagy-related proteins (p-mTOR, LC3B-II, P62). In vitro assays validated Aldometanib's mechanistic effects in D-gal-treated C8-D1A astrocytes and Neuro-2a cells. Aldometanib significantly mitigated D-gal-induced weight loss and cognitive deficits and alleviated neuronal atrophy and loss in the hippocampus and cortex. Aldometanib downregulated the expression of senescence markers P53, P21 and P16 and increased T-AOC levels. Mechanistically, Aldometanib specifically activated the AMPK/ACC pathway in neurons and astrocytes, suppressed mTOR phosphorylation and P62 accumulation, and enhanced autophagy both in vivo and in vitro. Aldometanib can effectively ameliorate the cognitive and physiological decline in aged mice by activating AMPK, suppressing mTOR and promoting autophagy, and enhancing antioxidant capacity. It represents a promising therapeutic candidate for age-related neurodegenerative diseases.
Indexed as
Identifiers
42730893What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.